Abstract
Disintegrin variants and pharmaceutical uses thereof are disclosed. The disintegrin variant includes an isolated polypeptide that has integrin .alpha.v.beta.3 receptor-antagonist activity and substantially reduced integrin .alpha.llb.beta.3 and/or .alpha.5.beta.1 receptor-blocking activity as compared to a wild-type disintegrin.
| Translated title of the contribution | 去整合蛋白變異體及其醫藥用途 |
|---|---|
| Original language | English |
| Patent number | 7943728 |
| Publication status | Published - 2008 Aug 7 |